CHOROBA REFLUKSOWA PRZEŁYKU.WYBRANE ZAGADNIENIA W ASPEKCIE NOWOCZESNYCH TECHNOLOGII LECZENIA

Anna Krakowczyk; Joanna Bączyk; Katarzyna Grudnik; Marta Tworuszka

CHOROBA REFLUKSOWA PRZEŁYKU.WYBRANE ZAGADNIENIA W ASPEKCIE NOWOCZESNYCH TECHNOLOGII LECZENIA

Autorzy

Anna Krakowczyk

Anna Krakowczyk1, Eliza Barczyk2, Joanna Bączyk2, Wojciech Dobczyński2, Katarzyna Grudnik2, Dariusz Kucias2 Studenckie Koło Naukowe im. Zbigniewa Religii przy Katedrze Biofizyki w Zabrzu, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach

Joanna Bączyk

Katarzyna Grudnik

Marta Tworuszka

Słowa kluczowe:

choroba refluksowa przełyku, nanotechnologia, nanocząsteczki chitozanu

Streszczenie

Abstrakt: Choroba refluksowa przełyku (GERD) jest jednym z częściej występujących przewlekłych schorzeń w krajach uprzemysłowionych i nadal stanowi istotny problem kliniczny. Zastosowanie farmaceutyków zazwyczaj łagodzi jedynie objawy GERD oraz związane jest z ryzykiem wystąpienia skutków ubocznych, a zabiegi chirurgiczne są inwazyjne dlatego nanotechnologia okazała się dobrą strategią w medycynie, oferującą znaczny potencjał i nowe możliwości ukierunkowanego dostarczania leków i zwiększoną skuteczność terapeutyczną. Postępy w technologii dostarczania leków mogą zrewolucjonizować sposób podawania leków na GERD i poprawić wyniki leczenia pacjentów, co ma związek z wykorzystaniem nanocząsteczek opartych na bazie chitozanu (CS). Kluczowe znaczenie ma opracowanie receptur leków, odpornych na kwaśne środowisko żołądka, niezbędne są dalsze badania w tym zakresie. W monografii zwrócono szczególną uwagę na problemy związane z leczeniem GERD i potencjał jaki stanowią nanocząsteczki w tej nowatorskiej strategii.

Słowa kluczowe: choroba refluksowa przełyku, nanotechnologia, nanocząsteczki chitozanu

Abstract: Gastroesophageal reflux disease (GERD) is one of the most common chronic diseases in industrialized countries and still constitutes a significant clinical problem. The use of pharmaceutical drugs usually only alleviates the symptoms of GERD and is associated with the risk of side effects. Surgical procedures are invasive, therefore nanotechnology has proven to be a good strategy in medicine. This strategy offers significant potential and new possibilities for targeted drug delivery and increased therapeutic effectiveness. Advance in drug delivery technology may revolutionize the way drugs are administered for GERD and improve patient treatment outcomes. This is related to the use of chitosan (CS)- based nanoparticles. It is crucial for development of drug formulations that are resistant to the acidic environment of the stomach. Anyway further research in this area is necessary. The monograph pays particular attention to problems related to the treatment of GERD and the potential of nanoparticles in this innovative strategy.

Keywords: gastroesophageal reflux disease, nanotechnology, chitosan nanoparticles

Bibliografia

REFERENCJE

Choroba refluksowa przełyku (GERD) Maria Korzonek, Agnieszka Dziergas, Magdalena Kuczyńska Via Medica 2014 Forum Medycyny Rodzinnej 2014, tom 8, nr 5.

Savarino V., Marabotto E., Zentilin P., Demarzo MG, De Bortoli N., Savarino E. Pharmacological treatment of gastroesophageal reflux disease: an update on the state of knowledge . 2021; 15 :1609–1621 doi: 10.2147/DDDT.S306371. [ Pub Med[ Google Scholar ]

Hom C, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease. Gastroenterol Clin North Am. 2013 Mar; 42(1): 71-91 [PubMed]

Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R., Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug; 101(8): 1900-20; quiz 1943[PubMed]

Maret-Ouda J., Markar S.R., Lagergren J. Gastroesophageal reflux disease a review. JAMA—J. Am. Med. Assoc. 2020;324:2536–2547. doi: 10.1001/jama.2020.21360. [PubMed] [Google Scholar]

Kawar N., Park S.G., Schwartz J.L., Callahan N., Obrez A., Yang B., Chen Z., Adami G.R. Salivary microbiome with gastroesophageal reflux disease and treatment. Sci. Rep. 2021; 11: 188. doi: 10.1038/s41598-020-80170-y [PubMed] [Google Scholar]

Newberry C., Lynch K. The role of diet in the development and management of gastroesophageal reflux disease: Why we feel the burn. J. Thorac. Dis. 2019;11:S1594–S1601. doi: 10.21037/jtd.2019.06.42. [PubMed] [Google Scholar]

Naik R.D., Meyers M.H., Vaezi M.F. Reflux Disease. Gastroenterol. Hepatol. 2020;16: 196– 205[PubMed] [Google Scholar]

Chhabra P., Ingole N. Gastroesophageal Reflux Disease (GERD): Highlighting Diagnosis, Treatment, and Lifestyle Changes. Cureus. 2022;14:e28563. doi: 10.7759/cureus.28563. [PubMed] [Google Scholar]

Yuan S., Larsson S.C. Adiposity, diabetes, lifestyle factors and risk of gastroesophageal reflux disease: A Mendelian randomization study. Eur. J. Epidemiol. 2022;37:747–754. [PubMed] [Google Scholar]

Taraszewska A. Risk factors for gastroesophageal reflux disease symptoms related to lifestyle and diet. Rocz. Panstw. Zakl. Hig. 2021;72:21–28. doi: 10.32394/rpzh.2021.0145. [PubMed] [Google Scholar]

Katz P.O., Dunbar K.B., Schnoll-Sussman F.H., Greer K.B., Yadlapati R., Spechler S.J. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am. J. Gastroenterol. 2022;117:27–56. doi: 10.14309/ajg.0000000000001538.[PubMed] [Google Scholar]

Shi Y., Chen L., Zhu M., Zhao Y. Nanomedicine. Springer; Singapore: 2020. The Future of Nanomedicine; pp. 1–28. [CrossRef]Google Scholar]

Snyder D.L., Katzka D.A. Complex Gastroesophageal Reflux Disease. Gastro. Hep. Adv. 2022;1:420–430. doi: 10.1016/j.gastha.2022.02.014. . [CrossRef] Google Scholar]

Lou J., Duan H., Qin Q., Teng Z., Gan F., Zhou X., Zhou X. Advances in Oral Drug Delivery Systems: Challenges and Opportunities. Pharmaceutics. 2023;15:484. doi: 10.3390/pharmaceutics15020484 [PubMed] [Google Scholar]

Afzal O., Altamimi A.S.A., Nadeem M.S., Alzarea S.I., Almalki W.H., Tariq A., Mubeen B., Murtaza B.N., Iftikhar S., Riaz N., et al. Nanoparticles in Drug Delivery: From History to Therapeutic Applications. Nanomaterials. 2022;12:4494. doi: 10.3390/nano12244494 [PubMed] [Google Scholar]

Iwakiri K., Fujiwara Y., Manabe N., Ihara E., Kuribayashi S., Akiyama J., Kondo T., Yamashita H., Ishimura N., Kitasako Y., et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J. Gastroenterol. 2022;57:267–285. doi: 10.1007/s00535-022-01861-z. .[PubMed] [Google Scholar]

Andrews W.G., Louie B.E. The relationship of hiatal hernia and gastroesophageal reflux symptoms—Two-sphincter hypothesis: A review. Ann. Laparosc. Endosc. Surg. 2021;6:41. doi: 10.21037/ales.2020.04.01. [CrossRef] Google Scholar]

Sawada A., Sergeev I., Sifrim D. Chapter 3—Obesity and impact on gastroesophageal reflux disease. In: Patel D., Kavitt R., Sarker S., Vaezi M., editors. Obesity and Esophageal Disorders. Academic Press; Cambridge, MA, USA: 2022. pp. 33–48. Google Scholar]

Noh J.H., Jung H.-Y. Role of Endoscopy in Motility Disorders of Upper Gastrointestinal Tract. J. Neurogastroenterol. Motil. 2023;29:7–19. doi: 10.5056/jnm22170. [PubMed] [CrossRef] Google Scholar]

Chen R.R., Chen Q.Z., Feng B.C., Wang M.F., Lin L., Ye B.X., Jiang L.Q. Characteristics of reflux and gastric electrical activity in gastroesophageal reflux disease with ineffective esophageal motility. J. Dig. Dis. 2023;24:2–9. doi: 10.1111/1751-2980.13164. [PubMed] [CrossRef] [ Google Scholar]

https://www.szpitalnaklinach.pl/nowe-zabiegi-z-wykorzystaniem-systemu-robotycznego-w-naszym-szpitalu-chirurgiczne-leczenie-przepukliny-rozworu-przelykowego/

AlAsseri N, Swennen G. Minimally invasive orthognathic surgery: a systematic review. Int J Oral Maxillofac Surg. 2018;47(10):1299‐1310.

Chirurgia Polska 2014,16,284-90[ Via Medica] [Google Scholar].

Jo Y. Proton Pump Inhibitors Reduce the Size and Acidity of the Gastric Acid Pocket. J. Neurogastroenterol. Motil. 2015;21:133–134. doi: 10.5056/jnm14152[PubMed] [CrossRef] Google Scholar]

Helgadottir H., Bjornsson E.S. Problems associated with deprescribing of proton pump inhibitors. Int. J. Mol. Sci. 2019;20:5469. doi: 10.3390/ijms20215469. [PubMed] [CrossRef] Google Scholar] .

Kahrilas P.J. Management of the Acid Pocket. Gastroenterol. Hepatol. 2014;10:587–589. [PubMed] [Google Scholar]

Kahrilas P.J., Mccoll K., Fox M., Rourke L.O., Sifrim D., Smout A.J.P.M., Boeckxstaens G. The Acid Pocket: A Target for Treatment in Reflux Disease? 2013, 108, 1058–1064. Am. J. Gastroenterol. 2013;108:1058–1064. doi: 10.1038/ajg.2013.132 [PubMed] [CrossRef] Google Scholar]

Kwiatek M.A., Roman S., Fareeduddin A., Pandolfino J.E., Kahrilas P.J. An alginate-antacid formulation (Gaviscon Double Action) can eliminate or displace the postprandial “acid pocket” in symptomatic GERD patients. Aliment. Pharmacol. Ther. 2011;34:59–66. doi: 10.1111/j.1365-2036.2011.04678.x. [PubMed] [CrossRef] Google Scholar]

Zhang M., Xiao Y., Chen M. The role of vonoprazan in patients with erosive esophagitis. Therap. Adv. Gastroenterol. 2022;15:17562848221122623. doi: 10.1177/17562848221122623 [PubMed] [CrossRef] Google Scholar]

Liang S.W., Wong M.W., Yi C.H., Liu T.T., Lei W.Y., Hung J.S., Lin L., Rogers B.D., Chen C.L. Current advances in the diagnosis and management of gastroesophageal reflux disease. Tzu. Chin. Med. J. 2022; 34: 402–408. doi: 10.4103/tcmj.tcmj_323_21. [PubMed] [CrossRef] Google Scholar]

Habu Y., Hamasaki R., Maruo M., Nakagawa T., Aono Y., Hachimine D. Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan. J. Gen. Fam. Med. 2021; 22: 237–245. doi: 10.1002/jgf2.429. [PubMed] [CrossRef] Google Scholar]

Rettura F., Bronzini F., Campigotto M., Lambiase C., Pancetti A., Berti G., Marchi S., de Bortoli N., Zerbib F., Savarino E., et al. Refractory Gastroesophageal Reflux Disease: A Management Update. Front. Med. 2021;8:765061. doi: 10.3389/fmed.2021.765061. [ PubMed] [CrossRef] Google Scholar]

Shibli F., Kitayama Y., Fass R. Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors. Curr. Gastroenterol. Rep. 2020; 22: 16. doi: 10.1007/s11894-020-0753-y. [ PubMed] [CrossRef] [ Google Scholar]

Norita K., Asanuma K., Koike T., Okata T., Fujiya T., Abe Y., Nakagawa K., Hatta W., Uno K., Nakamura T., et al. Impaired Mucosal Integrity in Proximal Esophagus Is Involved in Development of Proton Pump Inhibitor-Refractory Nonerosive Reflux Disease. Digestion. 2021;102:404–414. doi: 10.1159/000508661.[ PubMed] [CrossRef] [ Google Scholar]

Arabpour E., Khoshdel S., Akhgarzad A., Abdi M., Tabatabaie N., Alijanzadeh D., Abdehagh M. Baclofen as a therapeutic option for gastroesophageal reflux disease: A systematic review of clinical trials. Front. Med. 2023;10:997440. doi: 10.3389/fmed.2023.997440.[ PubMed] [CrossRef] [ Google Scholar]

Agostinis C., Bossi F., Mangogna A., Balduit A., Pacor M., Giacomello E., Belmonte B., Greco D., Rodolico V., Voinovich D., et al. Protective and regenerative effects of a novel medical device against esophageal mucosal damage using in vitro and ex vivo models. Biomed. Pharmacother. 2020;131:110752. doi: 10.1016/j.biopha.2020.110752. [ PubMed] [CrossRef] [ Google Scholar]

Liu D., Qian T., Sun S., Jiang J.J. Laryngopharyngeal reflux and inflammatory responses in mucosal barrier dysfunction of the upper aerodigestive tract. J. Inflamm. Res. 2020;13:1291–1304. doi: 10.2147/JIR.S282809. [ PubMed] [CrossRef] [ Google Scholar]

Hayakawa T., Kawasaki S., Hirayama Y., Tsutsui T., Sugiyama E., Adachi K., Kon R., Suematsu M., Sugiura Y. A thin layer of sucrose octasulfate protects the oesophageal mucosal epithelium in reflux oesophagitis. Sci. Rep. 2019;9:3559. doi: 10.1038/s41598-019-39087-4. [ PubMed] [CrossRef] [ Google Scholar]

Ustaoglu A., Nguyen A., Spechler S., Sifrim D., Souza R., Woodland P. Mucosal pathogenesis in gastro-esophageal reflux disease. Neurogastroenterol. Motil. 2020;32:e14022. doi: 10.1111/nmo.14022. [ PubMed] [CrossRef] [ Google Scholar]

Cioeta R., Muti P., Rigoni M., Morlando L., Siragusa F., Cossu A., Giovagnoni E. Effectiveness and tolerability of Poliprotect, a natural mucosal protective agent for gastroesophageal reflux disease and dyspepsia: Surveys from patients, physicians, and pharmacists. Front. Drug Saf. Regul. 2022;2:969831. doi: 10.3389/fdsfr.2022.969831. [CrossRef] [ Google Scholar]

Romano C., Scarpignato C. Pharmacologic treatment of GERD in adolescents: Is esophageal mucosal protection an option? Therap. Adv. Gastroenterol. 2022;15:17562848221115320. doi: 10.1177/17562848221115319. [ PubMed] [CrossRef] [ Google Scholar]

Altuwaijri M. Evidence-based treatment recommendations for gastroesophageal reflux disease during pregnancy. Medicine. 2022;101:e30487. doi: 10.1097/MD.0000000000030487. [ PubMed] [CrossRef] [ Google Scholar]

Nabi Z., Karyampudi A., Nageshwar Reddy D. Editor’s Pick: Refractory Gastroesophageal Reflux Disease: Pathophysiology, Diagnosis, and Management. EMJ Gastroenterol. 2019:62–71. doi: 10.33590/emjgastroenterol/10314735. [CrossRef] [ Google Scholar]

Enwereuzo O.O., Akakuru O.C., Uwaoma R.C., Elemike E.E., Akakuru O.U. Self-assembled membrane-polymer nanoparticles of top-notch tissue tolerance for the treatment of gastroesophageal reflux disease. J. Nanostruct. Chem. 2021;11:707–719. doi: 10.1007/s40097-021-00394-w. [CrossRef] [ Google Scholar]

Yusuf A., Almotairy A.R.Z., Henidi H., Alshehri O.Y., Aldughaim M.S. Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles’ Physicochemical Properties on Responses in Biological Systems. Polymers. 2023;15:1596. doi: 10.3390/polym15071596.[ PubMed] [CrossRef] [ Google Scholar]

Yan L., Shen J., Wang J., Yang X., Dong S., Lu S. Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology. Dose-Response. 2020;18:1559325820936161. doi: 10.1177/1559325820936161. [ PubMed] [CrossRef] [ Google Scholar]

Herdiana Y., Wathoni N., Gozali D., Shamsuddin S., Muchtaridi M. Chitosan-Based Nano-Smart Drug Delivery System in Breast Cancer Therapy. Pharmaceutics. 2023;15:879. doi: 10.3390/pharmaceutics15030879. [ PubMed] [CrossRef] [ Google Scholar]

Rezazadeh M., Safaran R., Minaiyan M., Mostafavi A. Preparation and characterization of Eudragit L 100-55/chitosan enteric nanoparticles containing omeprazole using general factorial design: In vitro/in vivo study. Res. Pharm. Sci. 2021;16:358–369. doi: 10.4103/1735-5362.319574. [ PubMed] [CrossRef] [ Google Scholar]

He X., Li K., Xing R., Liu S., Hu L., Li P. The production of fully deacetylated chitosan by compression method. Egypt. J. Aquat. Res. 2016;42:75–81. doi: 10.1016/j.ejar.2015.09.003. [CrossRef] [ Google Scholar]

Pellis A., Guebitz G.M., Nyanhongo G.S. Chitosan: Sources, Processing and Modification Techniques. Gels. 2022;8:393. doi: 10.3390/gels8070393. [ PubMed] [CrossRef] [ Google Scholar]

Liu Y., Sun M., Wang T., Chen X., Wang H. Chitosan-based self-assembled nanomaterials: Their application in drug delivery. View. 2021;2:20200069. doi: 10.1002/VIW.20200069[ PubMed] [CrossRef] [ Google Scholar]

Souza M.P.C., Sábio R.M., de Cassia Ribeiro T., de Cassia Ribeiro T., Dos Santos A.M., Meneguin A.B., Chorilli M. Highlighting the impact of chitosan on the development of gastroretentive drug delivery systems. Int. J. Biol. Macromol. 2020;159:804–822. doi: 10.1016/j.ijbiomac.2020.05.104. [ PubMed] [CrossRef] [ Google Scholar]

Krause J., Brokmann F., Rosenbaum C., Weitschies W. The challenges of drug delivery to the esophagus and how to overcome them. Expert Opin. Drug Deliv. 2022;19:119–131. doi: 10.1080/17425247.2022.2033206. [ PubMed] [CrossRef] [ Google Scholar]

Zainuddin S.Z., Hamid K.A. Chitosan-Based Oral Drug Delivery System for Peptide, Protein and Vaccine Delivery. In: Berrada M., editor. Chitin and Chitosan—Physicochemical Properties and Industrial Applications. IntechOpen; London, UK: 2021. pp. 1–22. [ PubMed] [ Google Scholar]

Manivannan S., Sivaraman H., Murugesan R., Narayan S. Omeprazole and H2S releasing agents encapsulated in chitosan nanoparticles to enhance healing process against indomethacin-induced gastric ulcer model. J. Mater. Res. 2023;38:3089–3109. doi: 10.1557/s43578-023-01030-9[CrossRef] [ Google Scholar]

Farhadnejad H., Mortazavi S.A., Jamshidfar S., Rakhshani A., Fatahi Y., Mahdieh A., Darbasizadeh B. Montmorillonite-Famotidine/Chitosan Bio-nanocomposite Hydrogels as a Mucoadhesive/Gastroretentive Drug Delivery System. Iran J. Pharm. Res. 2022;21:e127035. doi: 10.5812/ijpr-127035. [PubMed] [ Google Scholar] [CrossRef]

Małolepsza-Jarmołowska K. Influence of Pectin and Chitosan on The Properties of Gel Protecting Oesaphaegal Mucosa. Prog. Chem. Appl. Chitin Deriv. 2021;XXVI:162–169. doi: 10.15259/PCACD.26.014. [CrossRef] [ Google Scholar]

Jung D.H., Huh C.W., Lee S.K., Park J.C., Shin S.K., Lee Y.C. A systematic review and meta-analysis of randomized control trials: Combination treatment with proton pump inhibitor plus prokinetic for gastroesophageal reflux disease. J. Neurogastroenterol. Motil. 2021;27:165–175. doi: 10.5056/jnm2016 [ PubMed] [ Google Scholar] [CrossRef]

Zamani N.F., Sjahid A.S., Tuan Kamauzaman T.H., Lee Y.Y., Islam M.A. Efficacy and Safety of Domperidone in Combination with Proton Pump Inhibitors in Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. J. Clin. Med. 2022; 11: 5268. doi: 10.3390/jcm11185268. [ PubMed] [ Google Scholar] [CrossRef]

Isshi K., Furuhashi H., Nakada K. Therapeutic strategy for the patients with coexisting gastroesophageal reflux disease and postprandial distress syndrome of functional dyspepsia. JGH Open. 2020;4:582–588. doi: 10.1002/jgh3.12299. [PubMed] [Google Scholar] [CrossRef]

Mushtaq Z., Adeel B., Hussain T., Ali M., Ayyaz M., Joher I. A Prospective Observational Study Combinition of Proton Pump Inhibitors with Prokinetics in Gerd. Pakistan J. Med. Heal. Sci. 2022;16:427–429. doi: 10.53350/pjmhs22169427 [ Google Scholar] [CrossRef]

Vonoprazan lepszy od PPI. https://www.termedia.pl

Zhukova N.V., Kilessa V.V., Turna E.Y., Ulchenko I.G. Positive effect of rabeprazole/sulpiride combination therapy on bronchial asthma combined with gastroesophageal reflux disease. Pravara Med. Rev. 2020;12:11–22 [ Google Scholar]

Fashner J. Gastroesophageal Reflux Disease: A General Overview. HCA Healthc. J. Med. 2020; 1: 191–199. doi: 10.36518/2689-0216.1042 [ PubMed] [ Google Scholar] [CrossRef]

Rettura F., Bronzini F., Campigotto M., Lambiase C., Pancetti A., Berti G., Marchi S., de Bortoli N., Zerbib F., Savarino E., et al. Refractory Gastroesophageal Reflux Disease: A Management Update. Front. Med. 2021; 8: 765061. doi: 10.3389/fmed.2021.765061. [ PubMed] [ Google Scholar] [CrossRef]

Hano C., Abbasi B.H. Plant-based green synthesis of nanoparticles: Production, characterization and applications. Biomolecules. 2022;12:31. doi: 10.3390/biom12010031. [PubMed] [Google Scholar] [CrossRef]

Esquivel S.V., Bhatt H.N., Diwan R., Habib A., Lee W., Khatun Z., Nurunnabi M. β-Glucan and Fatty Acid Based Mucoadhesive Carrier for Gastrointestinal Tract Specific Local and Sustained Drug Delivery. Biomolecules. 2023;13:768. doi: 10.3390/biom13050768 [PubMed] [ Google Scholar] [CrossRef]

Gupta A., Akhtar J., Rastogi K.C., Badruddeen, Khan M.I., Ahmad M. Oral Disintegrating Tablets of Proton Pump Inhibitors for Chronic Gastroesophageal Reflux Disease: An Update. Curr. Drug Res. Rev. 2023;15:199–206. doi: 10.2174/2589977515666230221160449. [PubMed] [Google Scholar]